Table 1 Patient characteristics
Parameter | Tumor-stromal development (n = 112) | Tumor-stromal validation (n = 886) | Radiogenomic development (n = 91) | Prognostic validation 1 (n = 180) | Prognostic validation 2 (n = 61) |
|---|---|---|---|---|---|
Age | |||||
Median | 56.5 (30–90) | 59 (26–90) | 56 (29–82) | 42.9 (26.7–68.8) | 48 (29.7–72.4) |
Mean ± SD | 57.3 ± 14.6 | 58.9 ± 13.1 | 55.5 ± 11.4 | 47.7 ± 8.8 | 48.1 ± 9.8 |
ER | |||||
Positive | 78 (70) | 650 (73) | 75 (82) | 101 (56) | 28 (46) |
Negative | 21 (19) | 200 (23) | 16 (18) | 77 (43) | 20 (33) |
N/A | 13 (11) | 36 (4) | 0 | 2 (1) | 13 (21) |
PR | |||||
Positive | 68 (61) | 560 (63) | 66 (73) | 84 (47) | 22 (36) |
Negative | 31 (28) | 287 (32) | 25 (27) | 94 (52) | 26 (43) |
N/A | 13 (11) | 39 (5) | 0 | 2 (1) | 13 (21) |
HER2 | |||||
Positive | 23 (21) | 128 (14) | 13 (14) | 52 (29) | 14 (23) |
Negative | 56 (50) | 459 (52) | 44 (48) | 124 (69) | 31 (51) |
N/A | 33 (29) | 299 (34) | 34 (38) | 4 (2) | 16 (26) |
Follow-up (years) | |||||
Median | 3.45 (0.0–10.8) | 1.98 (0.0–23.6) | 2.99 (0.5–9.4) | 3.90(0.5–6.8) | 5.39 (0.3–9.8) |
Mean ± SD | 3.92 ± 2.37 | 3.23 ± 3.39 | 3.66 ± 2.11 | 3.84 ± 1.45 | 4.77 ± 2.75 |
Recurrence | |||||
Event | NA | NA | NA | 49(27) | 23(38) |
No-event | NA | NA | NA | 131(73) | 38(62) |
Death | |||||
Event | 43 (38) | 97 (11) | 2 (2) | 33 (18) | NA |
No-event | 69 (62) | 789 (89) | 89 (98) | 143 (80) | NA |
Unknown | 0 | 0 | 0 | 4 (2) | NA |